The MARINER trial^[*] of rivaroxaban after hospital discharge for medical patients at high risk of VTE

Summary

Hospital-associated venous thromboembolism (VTE) is a leading cause of premature death and disability worldwide. Evidence-based guidelines recommend that anticoagulant thromboprophylaxis be given to hospitalised medical patients at risk of VTE, but suggest against routine use of thromboprophylaxis beyond the hospital stay. The MARINER study is a randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of thromboprophylaxis using rivaroxaban, begun at hospital discharge and continued for 45 days, for preventing symptomatic VTE in high-risk medical patients. Eligible patients are identified using the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE VTE) risk score, combined with a laboratory test, D-dimer. The rivaroxaban regimen is 10 mg once daily for patients with CrCl ≥ 50 ml/min, or 7.5 mg once daily for patients with CrCl ≥ 30 ml/min and < 50 ml/ min. The primary efficacy outcome is the composite of symptomatic VTE (lower extremity deep-vein thrombosis and non-fatal pulmonary embolism) and VTE-related death. The principal safety outcome is major bleeding. A blinded clinical events committee adjudicates all suspected outcome events. The sample size is event-driven with an estimated total of 8,000 patients to acquire 161 primary outcome events. Study design features that distinguish MARINER from previous and ongoing thromboprophylaxis trials in medically ill patients are: (i) use of a validated risk assessment model (IMPROVE VTE) and D-dimer determination for identifying eligible patients at high risk of VTE, (ii) randomisation at the time of hospital discharge, (iii) a 45-day treatment period and (iv) restriction of the primary efficacy outcome to symptomatic VTE events.

Keywords

Venous thromboembolism - anticoagulants - deep-vein thrombosis - pulmonary embolism - thromboprophylaxis - rivaroxaban - medical patients

^* ClinicalTrials.gov Identifier: NCT02111564

• References

• 1 ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12: 1580-1590.
• 2 Jha AK, Larizgoitia I, Audrea-Lopez C. et al. The global burden of unsafe medical care: analytic modelling of observational studies. Br Med J Qual Saf 2013; 22: 809-815.
• 3 Cohen AT, Alikhan R, Arcelus JI. et al. Assessment of venous thromboembolism risk and the risk and benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94: 750-759.
• 4 Spyropoulos AC, Anderson FA, Fitzgerald G. et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706-714.
• 5 Hull RD, Merali T, Mills A. et al. Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors. Clin Appl Thromb Haemost 2013; 19: 357-362.
• 6 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep-vein thrombosis?. J Roy Soc Med 1989; 82: 203-205.
• 7 Anderson FA, Zayaruzny M, Heit JA. et al. Estimated annual number of US acute–care hospital patients at risk for venous thromboembolism. Am J Haematol 2007; 82: 777-782.
• 8 Cohen AT, Tapson VF, Bergmann JF. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394.
• 9 Kahn SR, Lim W, Dunn AS. et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Practice Guidelines. Chest 2012; 141: e195S-e226S.
• 10 Nicolaides AN, Fareed J, Kakkar AK. et al. Prevention and treatment of venous thromboembolism–International Consensus Statement. Int Angiol 2013; 32: 111-260.
• 11 Hull RD, Schellong SM, Tapson VF. et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153: 8-18.
• 12 Goldhaber SZ, Leizorovicz A, Kakkar AK. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167-2177.
• 13 Cohen AT, Spiro TE, Buller HR. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513-523.
• 14 Mahan CE, Fisher MD, Mills RM. et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patients population. Thromb Res 2013; 132: 520-526.
• 15 Sqizzato A, Ageno W. A new era for venous thromboembolism prevention in medical inpatients. Thromb Haemost 2014; 112: 627-628.
• 16 Mahan CE, Liu Y, Turpie AG. et al. External validation of a risk assessment model for venous thromboembolism in the hospitalized acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014; 112: 1-8.
• 17 Rosenberg D, Eichorn A, Alarcon M. et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014; 03: e001152.
• 18 Cohen AT, Spiro TE, Spyropoulos AC. et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014; 12: 479-487.
• 19 Mebazza A, Spiro TE, Buller HR. et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation 2014; 130: 410-418.
• 20 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
• 21 Fox KA, Piccini J, Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
• 22 Girgis IG, Patel MR, Peters GR. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol 2014; 54: 917-927.
• 23 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
• 24 Kittelson JM, Spyropoulos AC, Halperin JL. et al. Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. J Thromb Haemost 2013; 11: 1443-1448.
• 25 Cohen AT, Harrington R, Goldhaber SZ. et al. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J 2014; 167: 335-341.
• 26 US Department of Health and Human Services, Agency for Healthcare Research and Quality. Healthcare Cost and Utilisation Project. HCUP Projections. Cost of Inpatient Discharges 2003 to 2013. Report #2013–01.
• 27 Organisation for Economic Co-operation and Development. OECD health statistics. 2015 Available at: http://stats.oecd.org/Index.aspx?DataSet-Code=HEALTH_PROC Accessed: September 16, 2015.
• 28 Mahan CE, Fields LE, Mills RM. et al. All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients. Thromb Haemost 2015; 114: 685-694.